Eagle Pharmaceuticals, Inc. (EGRX)
After hours:
| Previous close | 45.67 |
| Open | 45.69 |
| Bid | 44.00 x 1100 |
| Ask | 46.75 x 1200 |
| Day's range | 45.69 - 46.93 |
| 52-week range | 36.48 - 58.25 |
| Volume | |
| Avg. volume | 133,463 |
| Market cap | 593.152M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 16.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Eagle Pharmaceuticals Reports First Quarter 2022 Results
Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income* was $4.10 per basic and $4.04 per diluted shareQ1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021Achieved sales of $34.3 million of vasopressin, with prior four weeks average market share of 24% per IQVIA dataAchieved sales of $37.2 million of PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®Agreed to terms to acquire Acacia Pharma Group plc, including
- GlobeNewswire
Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateMonday, May 9, 2022Time8:30 a.m. ETToll free (U.S.)800-891-3840Internatio
- GlobeNewswire
Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028
WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Hospira, Inc (“Hospira”). Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application (“NDA”) referencing BENDEKA®. The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstance
